WEKO3
アイテム
Efficacy and safety of tacrolimus as long-term monotherapy for myasthenia gravis.
https://kmu.repo.nii.ac.jp/records/196
https://kmu.repo.nii.ac.jp/records/1960289731a-cc1e-411d-9df3-9aa64f2f989c
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
論文要旨（要約） (284.1 kB)
|
||
|
審査結果要旨 (137.7 kB)
|
| Item type | 学位論文 / Thesis or Dissertation(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2021-10-15 | |||||
| タイトル | ||||||
| タイトル | Efficacy and safety of tacrolimus as long-term monotherapy for myasthenia gravis. | |||||
| タイトル | ||||||
| タイトル | Efficacy and safety of tacrolimus as long-term monotherapy for myasthenia gravis. | |||||
| 言語 | en | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_46ec | |||||
| 資源タイプ | thesis | |||||
| 別タイトル | ||||||
| その他のタイトル | 重症筋無力症に対する長期単剤療法としてのタクロリムスの有効性と安全性 | |||||
| 著者 |
井谷, 公美
× 井谷, 公美× Itani, Kumi× Nakamura, Masataka× Wate, Reika× Kaneko, Satoshi× Fujita, Kengo× Iida, Shin× Morise, Satoshi× Murakami, Aya× Kunieda, Takenobu× Takenouchi, Norihiro× Yakushiji, Yusuke× Kusaka, Hirofumi |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | The objective was to evaluate the long-term efficacy and safety of tacrolimus monotherapy in myasthenia gravis (MG) patients. Immunosuppressive drug-naïve MG patients were administered tacrolimus, followed by thymectomy in some of the cases according to the clinical guideline for MG. Additional aggressive immunosuppressive therapies were allowed if the patients without thymectomy did not achieve minimal manifestation (MM) or better status after 3 weeks of tacrolimus administration or in the thymectomized patients by 1-2 weeks after the operation (i.e., 1st evaluation). Of all 14 patients included in this study, 8 of them (57%) achieved MM or better status at the 1st evaluation, and the remaining 6 (43%), who had failed to gain MM or better status at the 1st evaluation, also achieved MM or better status with 1 course of aggressive immunosuppressive therapy. The quantitative MG (QMG) scores, MG-Activities of Daily Living (ADL) scales, and anti-acetylcholine receptor (AchR) antibody levels were significantly decreased at 6 months and maintained thereafter. At the end of the follow-up period (41-70 months), all patients were in MM or better status. None of the patients experienced severe adverse effects. Our small preliminary study indicates that long-term tacrolimus monotherapy is possibly effective and safe for MG patients. | |||||
| 学位名 | ||||||
| 学位名 | 博士（医学） | |||||
| 学位授与機関 | ||||||
| 学位授与機関名 | 関西医科大学 | |||||
| 学位授与年度 | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | 令和3年度 | |||||
| 学位授与年月日 | ||||||
| 学位授与年月日 | 2021-09-15 | |||||
| 学位授与番号 | ||||||
| 学位授与番号 | 課博第1108号 | |||||
| 書誌情報 |
Neuromuscular disorders : NMD en : Neuromuscular disorders : NMD 巻 31, 号 6, p. 512-518, 発行日 2021 |
|||||
| DOI | ||||||
| 表示名 | 10.1016/j.nmd.2021.02.010 | |||||
| URL | https://pubmed.ncbi.nlm.nih.gov/33903022/#:~:text=DOI%3A-,10.1016/j.nmd.2021.02.010,-Abstract | |||||
